Viagra and Cialis Found to Lower Risk of Cardiovascular Issues, Study Shows

A UTMB Health study reveals that erectile dysfunction medications like Viagra and Cialis are not only effective in treating ED but are also linked to lower risks of death, cardiovascular disease, and dementia.

Jaiden Quitzon

By 

Jaiden Quitzon

Published 

Dec 5, 2024

Viagra and Cialis Found to Lower Risk of Cardiovascular Issues, Study Shows

A significant research study conducted by the University of Texas Medical Branch at Galveston (UTMB) has uncovered unexpected advantages of erectile dysfunction medications like Viagra and Cialis. The study published in the American Journal of Medicine indicates that these medications could potentially lower the risk of death, cardiovascular disease, and dementia.

Under the guidance of Dr. Dietrich Jehle, Professor and Chair of UTMB’s Sealy Department of Emergency Medicine, the study revealed that medications for erectile dysfunction (ED) may provide cardiovascular advantages. The advantages encompass improved blood circulation, reduced blood pressure, enhanced endothelial performance, and anti-inflammatory properties, all of which play a role in promoting overall heart health. Additionally, Dr. Jehle observed that these medications might also enhance mental health by facilitating sexual activity, thereby improving quality of life.

The study assessed information from more than 500,000 men aged 40 and above who were diagnosed with erectile dysfunction from 2004 to 2021. The research emphasizes the connection between erectile dysfunction, lower urinary tract symptoms, and a heightened risk of cardiovascular problems, rendering the results significant for public health. The U.S. Food and Drug Administration (FDA) has approved these medications for the treatment of ED, pulmonary hypertension, and symptoms of an enlarged prostate. Yet, this study highlights their potential broader advantages.

Dr. Jehle highlighted the increasing significance of these treatments, given that cardiovascular disease continues to be the primary cause of death in the U.S. The findings highlight the extensive health implications of PDE-5 inhibitors, providing a fresh viewpoint on their contribution to enhancing long-term well-being.

Related Posts